MERTK抑制选择性激活DC-T细胞轴以提供抗白血病免疫
本研究探讨TAM家族激酶在白血病微环境中的免疫机制,发现宿主Mertk敲除或MERTK抑制剂MRX-2843可增加CD8α+树突状细胞并抑制白血病发生,且该作用依赖DC-T细胞轴;Tyro3敲除也具保护作用但机制不同,Axl敲除无影响。
要点
- 宿主Mertk敲除或MRX-2843增加CD8α+树突状细胞并抑制白血病发生。
- MRX-2843增加CD8+ T细胞数量并防止耗竭标志物诱导,涉及DC-T细胞轴。
- Tyro3敲除也保护小鼠对抗B-ALL,但机制与Mertk不同;Axl敲除无影响。
核心结论
- MERTK和TYRO3在白血病微环境中具有不同的免疫治疗靶点潜力,支持开发靶向MERTK和/或TYRO3的免疫疗法。
研究设计与样本
- 研究采用B细胞急性淋巴细胞白血病(B-ALL)模型,结合宿主Mertk、Tyro3、Axl敲除小鼠及MERTK抑制剂MRX-2843进行机制探索。
主要发现
- 宿主Mertk敲除或MERTK抑制剂MRX-2843增加白血病微环境中具有增强抗原呈递能力的CD8α+树突状细胞并抑制白血病发生。
- MRX-2843增加CD8+ T细胞数量并防止耗竭标志物诱导,提示DC-T细胞轴参与。
- 在Mertk-/-小鼠中,需同时清除CD8α+树突状细胞和CD8+ T细胞才能消除抗白血病免疫。
- Tyro3-/-小鼠也抵抗B-ALL,但未增加具有增强抗原呈递能力的CD8α+树突状细胞,且治疗活性对树突状细胞依赖较少。
- Axl-/-对白血病发生无影响。
关键数值与推荐
- 儿童ALL患者中高MERTK或低DC基因表达与不良预后相关。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TAM-family tyrosine kinases (TYRO3, AXL and MERTK) are potential cancer therapeutic targets. In previous studies MERTK inhibition in the immune microenvironment was therapeutically effective in a B-cell acute leukemia (B-ALL) model. Here, we probed anti-leukemia immune mechanisms and evaluated roles for TYRO3 and AXL in the leukemia microenvironment. Host Mertk knock-out or MERTK inhibitor MRX-2843 increased CD8α+ dendritic cells (DCs) with enhanced antigen-presentation capacity in the leukemia microenvironment and inhibited leukemogenesis. High MERTK or low DC gene expression were associated with poor prognosis in pediatric ALL patients, indicating the clinical relevance of these findings. MRX-2843 increased CD8+ T-cell numbers and prevented induction of exhaustion markers, implicating a DC - T-cell axis. Indeed, combined depletion of CD8α+ DCs and CD8+ T-cells was required to abrogate anti-leukemia immunity in Mertk-/- mice. Tyro3-/- mice were also protected against B-ALL, implicating TYRO3 as an immunotherapeutic target. In contrast to Mertk-/- mice, Tyro3-/- did not increase CD8α+ DCs with enhanced antigen-presentation capacity and therapeutic activity was less dependent on DCs, indicating a different immune mechanism. Axl-/- did not impact leukemogenesis. These data demonstrate differential TAM kinase roles in the leukemia microenvironment and provide rationale for development of MERTK and/or TYRO3-targeted immunotherapies.
引用
- Huelse JM, Bhasin SS, Jacobsen KM, et al. MERTK inhibition selectively activates a DC - T-cell axis to provide anti-leukemia immunity. Leukemia. 2024. PMID: 39322710. doi:10.1038/s41375-024-02408-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。